Sign in
Taking peoplePhase 2

BB-101 skin treatment for diabetic foot and lower leg ulcers

Tests BB-101 applied to the skin in people with diabetic foot ulcers.

Key facts

Who runs it
Blue Blood Biotech Corp.
Where
Taiwan5 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Status
Recruiting
Phase
Phase 2
People taking part
96 people, planned
Started
1 May 2024
Expected to end
31 Dec 2028
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • BB-101
Record updated
2 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 or type 2 diabetes who have a foot or lower leg ulcer that has not healed. It tests a liquid called BB-101, put on the ulcer, against a placebo.

Age
20 years or older
Sex
All sexes
Disease stage
At least one diabetic ulcer below the knee. It has not healed for 4 weeks or more despite care. Size 0.5 cm2 to 10 cm2. Wagner Grade 1 to Grade 2. No signs of infection. Blood flow to the leg must be good enough.
Earlier treatment
Must be under a doctor's care for diabetes. No growth factors such as becaplermin on the ulcer, no systemic corticosteroids, immunosuppressive agents, radiation or chemotherapy, and no other trial drug or device within 4 weeks before screening. No skin grafts, skin substitutes or hyperbaric oxygen therapy within 2 weeks. No topical antimicrobials or enzyme cleaning of the ulcer within 7 days.
Biomarker or test result
HbA1c ≤ 12% (108 mmol/mol). ALT and AST ≤ 2 × ULN. Serum creatinine ≤ 3 mg/dL (265 µmol/L). ANC ≥ 1,500 cells/μL, WBC ≥ 3,000 cells/μL, platelets ≥ 100,000 counts/μL. Hemoglobin ≥ 10 g/dL for men, ≥ 9 g/dL for women. Women need a negative pregnancy test.

Main reasons for not taking part

  • Infected ulcer, cellulitis, gangrene, or active bone infection needing antibiotics
  • Ulcer that shrank or grew by at least 30% after 2 weeks of standard care
  • Current cancer or past cancer, apart from some treated skin or cervical cancers
  • Sickle cell disease, vasculitis, or other conditions that slow healing
  • HIV-positive, breastfeeding, or drug or alcohol abuse

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Male or female, at least 20 years of age (inclusive) at the date of Screening
  • Subject or legally authorized representative who is able to understand the nature of this study and accepts to enter the study by signing written informed consent
  • Subject agrees to comply with ulcer care regimen for the duration of the study and is willing to return for all mandatory visits as defined in the protocol
  • Subject with Type 1 or Type 2 diabetes mellitus (criteria for the diagnosis of diabetes mellitus per American Diabetes Association) and is under the care of a physician for the management of diabetes mellitus
  • Subject with glycosylated hemoglobin (HbA1c) ≤ 12%
  • Subject with at least one diabetic foot ulcer meets the following criteria at Screening; Visit:
  • Located below knees; ii. Not healing for ≥ 4 weeks prior to Screening Visit despite appropriate care; iii. Ulcer size of ≥ 0.5 cm2 to ≤ 10 cm2 measured by the electronic measuring device following sharp debridement (if necessary) at Screening Visit and reconfirmed at Randomization Visit; iv. The largest ulcer will be selected as target ulcer. If ≥ 2 ulcers have the largest size, the one with the worst grade by Wagner Classification will be selected. If ≥ 2 ulcers have the largest size and grade, the one with longest duration will be selected; v. The target ulcer is classified as Grade 1 to Grade 2 according to Wagner Classification System for diabetic foot ulcer; vi. The target ulcer should be without clinical signs and symptoms of infection
  • Subject with adequate circulation to the affected lower limb, as demonstrated by at least one of the following criteria: i. Dorsum transcutaneous oximetry (TcPO2) ≥ 30 mmHg ii. Ankle brachial pressure index (ABPI) ≥ 0.7 iii. Absolute toe blood pressure > 30 mmHg iv. Doppler ultrasonography showed < 75% stenosis in the lower extremity arteries
  • Subject with adequate hepatic (ALT and AST ≤ 2 × ULN) and renal function (Serum creatinine ≤ 3 mg/dL)
  • Subject with adequate hematology function:; Absolute neutrophil count (ANC) ≥ 1,500 cells/μL ii. Total white blood cell (WBC) ≥ 3,000 cells/μL iii. Platelets ≥ 100,000 counts/μL iv. Hemoglobin ≥ 10 g/dL for male, ≥ 9 g/dL for female
  • Female subjects show negative serum pregnancy test results within 28 days prior to the first study treatment
  • All male subjects and female subjects with child-bearing potential (between puberty and 2 years after menopause) should use at least any one of the appropriate contraception methods during dosing and for at least 4 weeks after stopping study treatment

Who cannot take part

  • Purulent discharge; Subject with cellulitis or gangrene on the lower leg or foot with the target ulcer; Subject with active osteomyelitis, which requires systemic antibiotics. Systemic antibiotics must be complete or discontinued 1 week prior to Screening Visit; With target ulcer size decreased or increased by at least 30% after receiving 2 weeks of standard-of-care for diabetic foot ulcer before Randomization visit; Subject with another open ulcer < 2 cm away from target ulcer, on the same lower leg or foot; Subject with target ulcer caused primarily by etiologies not related to diabetes; Subject with target ulcers related to an incompletely healed amputation wound; Subject with any structural deformity of the lower leg or foot under study that would prevent off-loading of the target ulcer; subject with conditions which may interfere the off-loading effect may be excluded by the Investigators' judgment; Subject is scheduled to (or has received within 4 weeks prior to Screen Visit) receive any of the following medications or treatments:
  • Systemic corticosteroids (other than for inhalation), immunosuppressive agents, radiation therapy, or chemotherapeutic agents
  • Clinical signs and symptoms of infection of target ulcer assessed by clinical evaluation; The presence of infection is defined by ≥ 2 of the items presented as:
  • Platelet-derived product (e.g., becaplermin) or other growth factors on the target ulcer
  • Participation in a clinical trial of an investigational drug or device; Previous use of autologous graft or allogeneic graft, or dermal substitute or living skin equivalent (e.g., Dermagraft® or Apligraf® ) on the target ulcer or hyperbaric oxygen therapy within 2 weeks prior to Screening Visit; Use of any topical antimicrobials or enzymatic debridement treatment to treat the target ulcer within 7 days prior to Screening Visit; Subject with history of cancer or current cancer, with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to administration of any study agent; Vasculitis, connective tissue diseases, or any medical conditions known to impair ulcer healing, other than diabetes; Subject diagnosed with sickle cell disease; Subject with clinically significant electrocardiogram (ECG) abnormality, as determined by the Investigator; Poor nutritional status (serum albumin < 2.5 g/dL); C-reactive protein (CRP) > 50 mg/dL; Subject had a history of drug abuse or alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria; Patient with positive result of Human immunodeficiency virus (HIV); Female subject in lactation during the study period; Subject with underlying medical, mental or psychological conditions that would impair the treatment compliance, or in the opinion of the Investigator would not permit to participate in the study
  • Local swelling or induration
  • Erythema > 0.5 cm around wound
  • Local tenderness or pain
  • Local increased warmth

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.

The 3 groups in the trial

  • High Dose Dosing GroupExisting treatment, for comparison

    High Dose BB-101 topical solution will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.

    Treatment: BB-101

  • Low Dose Dosing GroupExisting treatment, for comparison

    Low Dose BB-101 topical solution will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.

    Treatment: BB-101

  • Placebo Dosing GroupPlacebo, for comparison

    Placebo will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.

    Treatment: BB-101

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Plain-language title
BB-101 skin treatment for diabetic foot and lower leg ulcersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
2 October 2026